Intuitive Surgical's latest quarterly results show the company generated $1.0B in free cash flow, representing a robust 12.4% of revenue. Over the past four quarters, ISRG has averaged $4.3B in free cash flow, or 10.3% of revenue, indicating the company's ability to consistently convert a meaningful portion of sales into cash flow. Furthermore, ISRG's return on invested capital (ROIC) remains strong at 31.6%, well above the company's weighted average cost of capital. This suggests Intuitive Surgical is deploying capital effectively and generating superior returns for shareholders. The market's confidence in ISRG's ability to maintain its margin profile and high ROIC is reflected in the stock's premium valuation, currently trading at 34.1x forward earnings. Despite this elevated multiple, the data indicates Intuitive Surgical continues to execute well and create shareholder value through disciplined capital allocation. Given Intuitive Surgical's robust free cash flow generation, consistent ROIC, and the market's apparent willingness to pay a premium for the company's earnings, I believe ISRG remains an attractive long-term investment for investors seeking exposure to the growing medical robotics industry. With the company's demonstrated ability to expand margins and deploy capital effectively, I see potential for ISRG to continue outperforming the broader market over the next 12-18 months.

Research these companies